Nxera Pharma

Nxera Pharma SOLTF Stock

$10.50   0.000000%
Add to favorites
Market Cap
$959.45M
LOW - HIGH [24H]
$10.50 - $10.50
VOLUME [24H]
$100.00
P/E Ratio
0
Earnings per share
-$0.40
ISIN
JP3431300007
Price   Prediction

Nxera Pharma Price Chart

Sorry, that's all we've gotfor now...

Nxera Pharma (SOLTF) stock price today is 10.5 USD on OTC Markets OTCPK (0% on the day). Updated .

Nxera Pharma SOLTF Financial and Trading Overview

Nxera Pharma stock price 10.5 USD
Previous Close 10.5 USD
Open 10.5 USD
Bid 10.59 USD x 20000
Ask 11.27 USD x 10000
Day's Range 10.5 - 10.5 USD
52 Week Range 4.9 - 10.93 USD
Volume 100 USD
Avg. Volume 98 USD
Market Cap 959.45M USD
Beta (5Y Monthly) 0.309
PE Ratio (TTM) N/A
EPS (TTM) -0.4 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date March 27, 2015
1y Target Est N/A

SOLTF Valuation Measures

Enterprise Value 36.3B USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.02701979
Price/Book (mrq) 2.3656712
Enterprise Value/Revenue 1.022
Enterprise Value/EBITDA 7.316

Trading Information

Nxera Pharma Stock Price History

Beta (5Y Monthly) 0.309
52-Week Change 95.53%
S&P500 52-Week Change 10.51%
52 Week High 10.93 USD
52 Week Low 4.9 USD
50-Day Moving Average 8.49 USD
200-Day Moving Average 6.54 USD

SOLTF Share Statistics

Avg. Volume (3 month) 98 USD
Avg. Daily Volume (10-Days) 85 USD
Shares Outstanding 91.38M
Float 75.49M
Short Ratio N/A
% Held by Insiders 18.18%
% Held by Institutions 33.19%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 100:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -15.18%
Operating Margin (ttm) 1.73%
Gross Margin 82.19%
EBITDA Margin 13.97%

Management Effectiveness

Return on Assets (ttm) 0.28%
Return on Equity (ttm) -8.30%

Income Statement

Revenue (ttm) 35.51B USD
Revenue Per Share (ttm) 390.98 USD
Quarterly Revenue Growth (yoy) 30.80%
Gross Profit (ttm) 29.19B USD
EBITDA 4.96B USD
Net Income Avi to Common (ttm) -5392999936 USD
Diluted EPS (ttm) -0.4
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 16.61B USD
Total Cash Per Share (mrq) 181.78 USD
Total Debt (mrq) 51.96B USD
Total Debt/Equity (mrq) 80.99 USD
Current Ratio (mrq) 2.558
Book Value Per Share (mrq) 4.4384866

Cash Flow Statement

Operating Cash Flow (ttm) 5.6B USD
Levered Free Cash Flow (ttm) -4309499904 USD

Profile of Nxera Pharma

Country United States
State N/A
City Minato
Address Midtown East
ZIP 107-0052
Phone 81 3 5962 5718
Website https://www.nxera.life
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 314

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.

Q&A For Nxera Pharma Stock

What is a current SOLTF stock price?

Nxera Pharma SOLTF stock price today per share is 10.5 USD.

How to purchase Nxera Pharma stock?

You can buy SOLTF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Nxera Pharma?

The stock symbol or ticker of Nxera Pharma is SOLTF.

Which industry does the Nxera Pharma company belong to?

The Nxera Pharma industry is Biotechnology.

How many shares does Nxera Pharma have in circulation?

The max supply of Nxera Pharma shares is 91.38M.

What is Nxera Pharma Price to Earnings Ratio (PE Ratio)?

Nxera Pharma PE Ratio is now.

What was Nxera Pharma earnings per share over the trailing 12 months (TTM)?

Nxera Pharma EPS is -0.4 USD over the trailing 12 months.

Which sector does the Nxera Pharma company belong to?

The Nxera Pharma sector is Healthcare.

$2.16T
Total marketcap
$70.95B
Total volume
BTC 57.99%   •   ETH 9.89%
Dominance
Select currency